Design, production and immunomodulatory potency of a novel allergen bioparticle
Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the ris...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-12, Vol.15 (12), p.e0242867 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | e0242867 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Gomord, Véronique Stordeur, Virginie Fitchette, Anne-Catherine Fixman, Elizabeth D Tropper, Guy Garnier, Lorna Desgagnes, Réjean Viel, Sébastien Couillard, Julie Beauverger, Guillaume Trepout, Sylvain Ward, Brian J van Ree, Ronald Faye, Loic Vézina, Louis-P |
| description | Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the risk of allergic side-effects. To become a more attractive alternative to lifelong symptomatic drug use, improvements to AIT are needed. Among the most promising new immunotherapy strategies is the use of bioparticles for the presentation of target antigen to the immune system as they can elicit strong T cell and B cell immune responses. Virus-like particles (VLPs) are a specific class of bioparticles in which the structural and immunogenic constituents are from viral origin. However, VLPs are ill-suited for use in AIT as their antigenicity is linked to structure. Recently, synthetic biology has been used to produce artificial modular bioparticles, in which supramolecular assemblies are made of elements from heterogeneous biological sources promoting the design and use of in vivo-assembling enveloped bioparticles for viral and non-viral antigens presentation. We have used a coiled-coil hybrid assembly for the design of an enveloped bioparticle (eBP) that present trimers of the Der p 2 allergen at its surface, This bioparticle was produced as recombinant and in vivo assembled eBPs in plant. This allergen biotherapeutic was used to demonstrate i) the capacity of plants to produce synthetic supramolecular allergen bioparticles, and ii) the immunomodulatory potential of naturally-assembled allergen bioparticles. Our results show that allergens exposed on eBPs induced a very strong IgG response consisting predominantly of IgG2a in favor of the TH1 response. Finally, our results demonstrate that rDer p 2 present on the surface of BPs show a very limited potential to stimulate the basophil degranulation of patient allergic to this allergen which is predictive of a high safety potential. |
| doi_str_mv | 10.1371/journal.pone.0242867 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2466021332</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A643422633</galeid><doaj_id>oai_doaj_org_article_c2b0a900153542a499e9a163fb495643</doaj_id><sourcerecordid>A643422633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-913f7d127a29b7e04ee42a977ef7d30a3479d7fbd2d72e72b518a62cb6830f993</originalsourceid><addsrcrecordid>eNqNkltr3DAQhU1padK0_6C0hkJpobvVxZZWL4WQ3hYCC729Ctkee7XIkiPZIfvvI3edsC55KH6wGX1zdGZ8kuQlRktMOf64c4O3yiw7Z2GJSEZWjD9KTrGgZMEIoo-Pvk-SZyHsEMrpirGnyQmlJBc5wafJ5jME3dgPaeddNZS9djZVtkp12w7WtbFmVO_8Pu1cD7bcp65OVWrdNZhUGQO-AZsW2nXK97o08Dx5UisT4MX0Pkt-f_3y6-L74nLzbX1xfrkomSD9QmBa8woTrogoOKAMICNKcA6xTJGiGRcVr4uKVJwAJ0WOV4qRsmArimoh6Fny-qDbGRfktIsgScYYIjjOF4n1gaic2snO61b5vXRKy78F5xs5eZYlKZASCOGc5tFGJgQIhRmti0zkLKNR69N021C0UJVge6_MTHR-YvVWNu5aco44wygKvJsEvLsaIPSy1aEEY5QFNxx8E0FWdJzszT_ow9NNVKPiANrWLt5bjqLyPDrOCGF09L18gIpPBa0uY3BqHeuzhvezhsj0cNM3aghBrn_--H9282fOvj1it6BMvw3ODGPewhzMDmDpXQge6vslYyTH3N9tQ465l1PuY9ur4x9033QXdHoLBWX8Fg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2466021332</pqid></control><display><type>article</type><title>Design, production and immunomodulatory potency of a novel allergen bioparticle</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Gomord, Véronique ; Stordeur, Virginie ; Fitchette, Anne-Catherine ; Fixman, Elizabeth D ; Tropper, Guy ; Garnier, Lorna ; Desgagnes, Réjean ; Viel, Sébastien ; Couillard, Julie ; Beauverger, Guillaume ; Trepout, Sylvain ; Ward, Brian J ; van Ree, Ronald ; Faye, Loic ; Vézina, Louis-P</creator><contributor>Chapoval, Svetlana P.</contributor><creatorcontrib>Gomord, Véronique ; Stordeur, Virginie ; Fitchette, Anne-Catherine ; Fixman, Elizabeth D ; Tropper, Guy ; Garnier, Lorna ; Desgagnes, Réjean ; Viel, Sébastien ; Couillard, Julie ; Beauverger, Guillaume ; Trepout, Sylvain ; Ward, Brian J ; van Ree, Ronald ; Faye, Loic ; Vézina, Louis-P ; Chapoval, Svetlana P.</creatorcontrib><description>Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the risk of allergic side-effects. To become a more attractive alternative to lifelong symptomatic drug use, improvements to AIT are needed. Among the most promising new immunotherapy strategies is the use of bioparticles for the presentation of target antigen to the immune system as they can elicit strong T cell and B cell immune responses. Virus-like particles (VLPs) are a specific class of bioparticles in which the structural and immunogenic constituents are from viral origin. However, VLPs are ill-suited for use in AIT as their antigenicity is linked to structure. Recently, synthetic biology has been used to produce artificial modular bioparticles, in which supramolecular assemblies are made of elements from heterogeneous biological sources promoting the design and use of in vivo-assembling enveloped bioparticles for viral and non-viral antigens presentation. We have used a coiled-coil hybrid assembly for the design of an enveloped bioparticle (eBP) that present trimers of the Der p 2 allergen at its surface, This bioparticle was produced as recombinant and in vivo assembled eBPs in plant. This allergen biotherapeutic was used to demonstrate i) the capacity of plants to produce synthetic supramolecular allergen bioparticles, and ii) the immunomodulatory potential of naturally-assembled allergen bioparticles. Our results show that allergens exposed on eBPs induced a very strong IgG response consisting predominantly of IgG2a in favor of the TH1 response. Finally, our results demonstrate that rDer p 2 present on the surface of BPs show a very limited potential to stimulate the basophil degranulation of patient allergic to this allergen which is predictive of a high safety potential.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0242867</identifier><identifier>PMID: 33259521</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Allergens ; Allergens - biosynthesis ; Allergens - chemistry ; Allergens - immunology ; Allergy ; Aluminum ; Amino Acid Sequence ; Animals ; Antigen presentation ; Antigenicity ; Antigens ; Antigens, Dermatophagoides - immunology ; Assembling ; Basophils - immunology ; Biological products ; Biology and Life Sciences ; Bronchial Hyperreactivity - immunology ; Bronchoalveolar Lavage Fluid ; Care and treatment ; Degranulation ; Design ; DNA - metabolism ; Female ; Food allergies ; Human papillomavirus ; Humans ; Hypersensitivity - immunology ; Immune response (cell-mediated) ; Immune system ; Immunization ; Immunogenicity ; Immunoglobulin G ; Immunomodulation ; Immunomodulation - immunology ; Immunosuppressive agents ; Immunotherapy ; Influenza ; Lymphocytes ; Lymphocytes T ; Medical treatment ; Medicine and Health Sciences ; Methods ; Mice, Inbred BALB C ; Modular structures ; Nanoparticles - chemistry ; Nanoparticles - ultrastructure ; People and Places ; Peptides ; Production processes ; Protein Processing, Post-Translational ; Proteins ; Recombinant Proteins - biosynthesis ; Recombinant Proteins - chemistry ; Side effects ; Synthetic biology ; Synthetic products ; Trimers ; Vaccines ; Virus-like particles ; Viruses</subject><ispartof>PloS one, 2020-12, Vol.15 (12), p.e0242867</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Gomord et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Gomord et al 2020 Gomord et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-913f7d127a29b7e04ee42a977ef7d30a3479d7fbd2d72e72b518a62cb6830f993</citedby><cites>FETCH-LOGICAL-c692t-913f7d127a29b7e04ee42a977ef7d30a3479d7fbd2d72e72b518a62cb6830f993</cites><orcidid>0000-0003-4884-9874 ; 0000-0001-7062-9136 ; 0000-0002-5085-443X ; 0000-0002-5822-407X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707610/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707610/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79472,79473</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33259521$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Chapoval, Svetlana P.</contributor><creatorcontrib>Gomord, Véronique</creatorcontrib><creatorcontrib>Stordeur, Virginie</creatorcontrib><creatorcontrib>Fitchette, Anne-Catherine</creatorcontrib><creatorcontrib>Fixman, Elizabeth D</creatorcontrib><creatorcontrib>Tropper, Guy</creatorcontrib><creatorcontrib>Garnier, Lorna</creatorcontrib><creatorcontrib>Desgagnes, Réjean</creatorcontrib><creatorcontrib>Viel, Sébastien</creatorcontrib><creatorcontrib>Couillard, Julie</creatorcontrib><creatorcontrib>Beauverger, Guillaume</creatorcontrib><creatorcontrib>Trepout, Sylvain</creatorcontrib><creatorcontrib>Ward, Brian J</creatorcontrib><creatorcontrib>van Ree, Ronald</creatorcontrib><creatorcontrib>Faye, Loic</creatorcontrib><creatorcontrib>Vézina, Louis-P</creatorcontrib><title>Design, production and immunomodulatory potency of a novel allergen bioparticle</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the risk of allergic side-effects. To become a more attractive alternative to lifelong symptomatic drug use, improvements to AIT are needed. Among the most promising new immunotherapy strategies is the use of bioparticles for the presentation of target antigen to the immune system as they can elicit strong T cell and B cell immune responses. Virus-like particles (VLPs) are a specific class of bioparticles in which the structural and immunogenic constituents are from viral origin. However, VLPs are ill-suited for use in AIT as their antigenicity is linked to structure. Recently, synthetic biology has been used to produce artificial modular bioparticles, in which supramolecular assemblies are made of elements from heterogeneous biological sources promoting the design and use of in vivo-assembling enveloped bioparticles for viral and non-viral antigens presentation. We have used a coiled-coil hybrid assembly for the design of an enveloped bioparticle (eBP) that present trimers of the Der p 2 allergen at its surface, This bioparticle was produced as recombinant and in vivo assembled eBPs in plant. This allergen biotherapeutic was used to demonstrate i) the capacity of plants to produce synthetic supramolecular allergen bioparticles, and ii) the immunomodulatory potential of naturally-assembled allergen bioparticles. Our results show that allergens exposed on eBPs induced a very strong IgG response consisting predominantly of IgG2a in favor of the TH1 response. Finally, our results demonstrate that rDer p 2 present on the surface of BPs show a very limited potential to stimulate the basophil degranulation of patient allergic to this allergen which is predictive of a high safety potential.</description><subject>Allergens</subject><subject>Allergens - biosynthesis</subject><subject>Allergens - chemistry</subject><subject>Allergens - immunology</subject><subject>Allergy</subject><subject>Aluminum</subject><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Antigen presentation</subject><subject>Antigenicity</subject><subject>Antigens</subject><subject>Antigens, Dermatophagoides - immunology</subject><subject>Assembling</subject><subject>Basophils - immunology</subject><subject>Biological products</subject><subject>Biology and Life Sciences</subject><subject>Bronchial Hyperreactivity - immunology</subject><subject>Bronchoalveolar Lavage Fluid</subject><subject>Care and treatment</subject><subject>Degranulation</subject><subject>Design</subject><subject>DNA - metabolism</subject><subject>Female</subject><subject>Food allergies</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Hypersensitivity - immunology</subject><subject>Immune response (cell-mediated)</subject><subject>Immune system</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Immunoglobulin G</subject><subject>Immunomodulation</subject><subject>Immunomodulation - immunology</subject><subject>Immunosuppressive agents</subject><subject>Immunotherapy</subject><subject>Influenza</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Medical treatment</subject><subject>Medicine and Health Sciences</subject><subject>Methods</subject><subject>Mice, Inbred BALB C</subject><subject>Modular structures</subject><subject>Nanoparticles - chemistry</subject><subject>Nanoparticles - ultrastructure</subject><subject>People and Places</subject><subject>Peptides</subject><subject>Production processes</subject><subject>Protein Processing, Post-Translational</subject><subject>Proteins</subject><subject>Recombinant Proteins - biosynthesis</subject><subject>Recombinant Proteins - chemistry</subject><subject>Side effects</subject><subject>Synthetic biology</subject><subject>Synthetic products</subject><subject>Trimers</subject><subject>Vaccines</subject><subject>Virus-like particles</subject><subject>Viruses</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNkltr3DAQhU1padK0_6C0hkJpobvVxZZWL4WQ3hYCC729Ctkee7XIkiPZIfvvI3edsC55KH6wGX1zdGZ8kuQlRktMOf64c4O3yiw7Z2GJSEZWjD9KTrGgZMEIoo-Pvk-SZyHsEMrpirGnyQmlJBc5wafJ5jME3dgPaeddNZS9djZVtkp12w7WtbFmVO_8Pu1cD7bcp65OVWrdNZhUGQO-AZsW2nXK97o08Dx5UisT4MX0Pkt-f_3y6-L74nLzbX1xfrkomSD9QmBa8woTrogoOKAMICNKcA6xTJGiGRcVr4uKVJwAJ0WOV4qRsmArimoh6Fny-qDbGRfktIsgScYYIjjOF4n1gaic2snO61b5vXRKy78F5xs5eZYlKZASCOGc5tFGJgQIhRmti0zkLKNR69N021C0UJVge6_MTHR-YvVWNu5aco44wygKvJsEvLsaIPSy1aEEY5QFNxx8E0FWdJzszT_ow9NNVKPiANrWLt5bjqLyPDrOCGF09L18gIpPBa0uY3BqHeuzhvezhsj0cNM3aghBrn_--H9282fOvj1it6BMvw3ODGPewhzMDmDpXQge6vslYyTH3N9tQ465l1PuY9ur4x9033QXdHoLBWX8Fg</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Gomord, Véronique</creator><creator>Stordeur, Virginie</creator><creator>Fitchette, Anne-Catherine</creator><creator>Fixman, Elizabeth D</creator><creator>Tropper, Guy</creator><creator>Garnier, Lorna</creator><creator>Desgagnes, Réjean</creator><creator>Viel, Sébastien</creator><creator>Couillard, Julie</creator><creator>Beauverger, Guillaume</creator><creator>Trepout, Sylvain</creator><creator>Ward, Brian J</creator><creator>van Ree, Ronald</creator><creator>Faye, Loic</creator><creator>Vézina, Louis-P</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4884-9874</orcidid><orcidid>https://orcid.org/0000-0001-7062-9136</orcidid><orcidid>https://orcid.org/0000-0002-5085-443X</orcidid><orcidid>https://orcid.org/0000-0002-5822-407X</orcidid></search><sort><creationdate>20201201</creationdate><title>Design, production and immunomodulatory potency of a novel allergen bioparticle</title><author>Gomord, Véronique ; Stordeur, Virginie ; Fitchette, Anne-Catherine ; Fixman, Elizabeth D ; Tropper, Guy ; Garnier, Lorna ; Desgagnes, Réjean ; Viel, Sébastien ; Couillard, Julie ; Beauverger, Guillaume ; Trepout, Sylvain ; Ward, Brian J ; van Ree, Ronald ; Faye, Loic ; Vézina, Louis-P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-913f7d127a29b7e04ee42a977ef7d30a3479d7fbd2d72e72b518a62cb6830f993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Allergens</topic><topic>Allergens - biosynthesis</topic><topic>Allergens - chemistry</topic><topic>Allergens - immunology</topic><topic>Allergy</topic><topic>Aluminum</topic><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Antigen presentation</topic><topic>Antigenicity</topic><topic>Antigens</topic><topic>Antigens, Dermatophagoides - immunology</topic><topic>Assembling</topic><topic>Basophils - immunology</topic><topic>Biological products</topic><topic>Biology and Life Sciences</topic><topic>Bronchial Hyperreactivity - immunology</topic><topic>Bronchoalveolar Lavage Fluid</topic><topic>Care and treatment</topic><topic>Degranulation</topic><topic>Design</topic><topic>DNA - metabolism</topic><topic>Female</topic><topic>Food allergies</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Hypersensitivity - immunology</topic><topic>Immune response (cell-mediated)</topic><topic>Immune system</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Immunoglobulin G</topic><topic>Immunomodulation</topic><topic>Immunomodulation - immunology</topic><topic>Immunosuppressive agents</topic><topic>Immunotherapy</topic><topic>Influenza</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Medical treatment</topic><topic>Medicine and Health Sciences</topic><topic>Methods</topic><topic>Mice, Inbred BALB C</topic><topic>Modular structures</topic><topic>Nanoparticles - chemistry</topic><topic>Nanoparticles - ultrastructure</topic><topic>People and Places</topic><topic>Peptides</topic><topic>Production processes</topic><topic>Protein Processing, Post-Translational</topic><topic>Proteins</topic><topic>Recombinant Proteins - biosynthesis</topic><topic>Recombinant Proteins - chemistry</topic><topic>Side effects</topic><topic>Synthetic biology</topic><topic>Synthetic products</topic><topic>Trimers</topic><topic>Vaccines</topic><topic>Virus-like particles</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gomord, Véronique</creatorcontrib><creatorcontrib>Stordeur, Virginie</creatorcontrib><creatorcontrib>Fitchette, Anne-Catherine</creatorcontrib><creatorcontrib>Fixman, Elizabeth D</creatorcontrib><creatorcontrib>Tropper, Guy</creatorcontrib><creatorcontrib>Garnier, Lorna</creatorcontrib><creatorcontrib>Desgagnes, Réjean</creatorcontrib><creatorcontrib>Viel, Sébastien</creatorcontrib><creatorcontrib>Couillard, Julie</creatorcontrib><creatorcontrib>Beauverger, Guillaume</creatorcontrib><creatorcontrib>Trepout, Sylvain</creatorcontrib><creatorcontrib>Ward, Brian J</creatorcontrib><creatorcontrib>van Ree, Ronald</creatorcontrib><creatorcontrib>Faye, Loic</creatorcontrib><creatorcontrib>Vézina, Louis-P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale in Context : Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gomord, Véronique</au><au>Stordeur, Virginie</au><au>Fitchette, Anne-Catherine</au><au>Fixman, Elizabeth D</au><au>Tropper, Guy</au><au>Garnier, Lorna</au><au>Desgagnes, Réjean</au><au>Viel, Sébastien</au><au>Couillard, Julie</au><au>Beauverger, Guillaume</au><au>Trepout, Sylvain</au><au>Ward, Brian J</au><au>van Ree, Ronald</au><au>Faye, Loic</au><au>Vézina, Louis-P</au><au>Chapoval, Svetlana P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, production and immunomodulatory potency of a novel allergen bioparticle</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>15</volume><issue>12</issue><spage>e0242867</spage><pages>e0242867-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the risk of allergic side-effects. To become a more attractive alternative to lifelong symptomatic drug use, improvements to AIT are needed. Among the most promising new immunotherapy strategies is the use of bioparticles for the presentation of target antigen to the immune system as they can elicit strong T cell and B cell immune responses. Virus-like particles (VLPs) are a specific class of bioparticles in which the structural and immunogenic constituents are from viral origin. However, VLPs are ill-suited for use in AIT as their antigenicity is linked to structure. Recently, synthetic biology has been used to produce artificial modular bioparticles, in which supramolecular assemblies are made of elements from heterogeneous biological sources promoting the design and use of in vivo-assembling enveloped bioparticles for viral and non-viral antigens presentation. We have used a coiled-coil hybrid assembly for the design of an enveloped bioparticle (eBP) that present trimers of the Der p 2 allergen at its surface, This bioparticle was produced as recombinant and in vivo assembled eBPs in plant. This allergen biotherapeutic was used to demonstrate i) the capacity of plants to produce synthetic supramolecular allergen bioparticles, and ii) the immunomodulatory potential of naturally-assembled allergen bioparticles. Our results show that allergens exposed on eBPs induced a very strong IgG response consisting predominantly of IgG2a in favor of the TH1 response. Finally, our results demonstrate that rDer p 2 present on the surface of BPs show a very limited potential to stimulate the basophil degranulation of patient allergic to this allergen which is predictive of a high safety potential.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33259521</pmid><doi>10.1371/journal.pone.0242867</doi><tpages>e0242867</tpages><orcidid>https://orcid.org/0000-0003-4884-9874</orcidid><orcidid>https://orcid.org/0000-0001-7062-9136</orcidid><orcidid>https://orcid.org/0000-0002-5085-443X</orcidid><orcidid>https://orcid.org/0000-0002-5822-407X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-12, Vol.15 (12), p.e0242867 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2466021332 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Allergens Allergens - biosynthesis Allergens - chemistry Allergens - immunology Allergy Aluminum Amino Acid Sequence Animals Antigen presentation Antigenicity Antigens Antigens, Dermatophagoides - immunology Assembling Basophils - immunology Biological products Biology and Life Sciences Bronchial Hyperreactivity - immunology Bronchoalveolar Lavage Fluid Care and treatment Degranulation Design DNA - metabolism Female Food allergies Human papillomavirus Humans Hypersensitivity - immunology Immune response (cell-mediated) Immune system Immunization Immunogenicity Immunoglobulin G Immunomodulation Immunomodulation - immunology Immunosuppressive agents Immunotherapy Influenza Lymphocytes Lymphocytes T Medical treatment Medicine and Health Sciences Methods Mice, Inbred BALB C Modular structures Nanoparticles - chemistry Nanoparticles - ultrastructure People and Places Peptides Production processes Protein Processing, Post-Translational Proteins Recombinant Proteins - biosynthesis Recombinant Proteins - chemistry Side effects Synthetic biology Synthetic products Trimers Vaccines Virus-like particles Viruses |
| title | Design, production and immunomodulatory potency of a novel allergen bioparticle |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T22%3A26%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20production%20and%20immunomodulatory%20potency%20of%20a%20novel%20allergen%20bioparticle&rft.jtitle=PloS%20one&rft.au=Gomord,%20V%C3%A9ronique&rft.date=2020-12-01&rft.volume=15&rft.issue=12&rft.spage=e0242867&rft.pages=e0242867-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0242867&rft_dat=%3Cgale_plos_%3EA643422633%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2466021332&rft_id=info:pmid/33259521&rft_galeid=A643422633&rft_doaj_id=oai_doaj_org_article_c2b0a900153542a499e9a163fb495643&rfr_iscdi=true |